Chardan lowered the firm’s price target on Unity Biotechnology (UBX) to $4 from $6 and keeps a Buy rating on the shares after the company announced topline 24- and 36-week results from its Phase 2b ASPIRE study of the senolytic Bcl-xL inhibitor UBX1325 in diabetic macular edema. The study failed to meet its primary endpoint of non-inferiority to aflibercept, the analyst tells investors in a research note. The firm says the miss narrows the path forward For UBX1325.
Claim 50% Off TipRanks Premium and Invest with Confidence
- Unlock hedge-fund level data and powerful investing tools designed to help you make smarter, sharper decisions
- Stay ahead of the market with the latest news and analysis so your portfolio is always positioned for maximum potential
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on UBX:
- Positive Outlook for Unity Biotechnology Despite Initial Setback in UBX1325 Study
- Unity Biotechnology announces results from ASPIRE Phase 2b study in DME
- Unity Biotechnology Appoints Dr. Yehia Hashad to Board
- Unity Biotechnology appoints Hashad to board of directors
- Buy Rating Reaffirmed for Unity Biotechnology Amid Promising Developments in DME Treatment